The Top 5 Biosimilars Articles for the Week of May 18

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of May 18, 2020.

Number 5: Amid the disruption caused by the new COVID-19 pandemic Outlook Therapeutics is pioneering its own bevacizumab biosimilar and expects to begin reporting topline data from clinical trials later this year.

Number 4: India entered the biosimilar market early and has nearly 100 approved biosimilars, but experts say its regulatory system is not considered world-class, which may hinder international marketing of these products.

Number 3: There’s not enough study on the effects of international reference pricing, but it is likely to stifle innovation and create access problems, according to an expert panel at Virtual ISPOR 2020 conference.

Number 2: If it has strong intentions to develop the IL-23 agent brazikumab for commercialization, AstraZeneca did not show its hand when it acknowledged receipt of the agent from Allergan last week.

Number 1: Celltrion is pinning its hopes on a higher-concentration formulation of its adalimumab biosimilar to gain elbow room among multiple competing products.

To read all of these articles and more, visit centerforbiosimilars.com.